ACADIA Pharmaceuticals Inc (NASDAQ:ACAD)
| 23.27 Delayed Data As of Sep 25 |  -0.27 / -1.15%Today’s Change | 13.73 Today|||52-Week Range 33.99 | +46.17% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $3.9B |
Company Description
ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
Contact Information
ACADIA Pharmaceuticals, Inc. 12830 El Camino Real San Diego California 92130-3331 |
Employees
Shareholders
| Other institutional | 65.86% |
| Individual stakeholders | 32.63% |
| Mutual fund holders | 31.95% |
Top Executives
| Stephen R. Davis | Chief Executive Officer & Director |
| Brendan P. Teehan | Chief Operating Officer, EVP & Head-Commercial |
| Mark C. Schneyer | Chief Financial Officer & Executive Vice President |
| Ponni Subbiah | Chief Medical Officer & Senior Vice President |
| Sanjeev Pathak | Senior Vice President & Head-Clinical Development |
